Pfizer (PFE) and BioNTech (BNTX) announced the companies have received Fast Track Designation from the U.S. FDA for their mRNA-based combination vaccine candidate for influenza and COVID-19, which aims to help prevent two respiratory diseases with a single injection. The vaccine candidate is based on BioNTech’s proprietary mRNA platform technology and contains mRNA strands encoding the wild-type spike protein of SARS-CoV-2 and the spike protein of the Omicron sublineages BA.4/BA.5, as well as mRNA strands encoding the hemagglutinin of four different influenza strains, recommended for the Northern Hemisphere 2022/23 by the World Health Organization.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PFE:
- Pfizer, BioNTech announce EUA for bivalent COVID vaccine for children under 5
- Two “Perfect 10” Healthcare Stocks to Beat the Market
- #SocialStocks: EU rules against Meta, despite attempts to settle
- Prometheus price target raised to $114 from $67 at Piper Sandler
- Pfizer: FDA accepts for priority review BLA for RSV vaccine candidate, RSVpreF